Best Penny Stocks Under 10 Cents Right Now → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.10 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.10. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - FiskerNYSE:FSRStock Price: $0.09 (-$0.04)P/E Ratio: -0.04Market Cap: $31.45 millionAverage Trading Volume: 85.29 million sharesConsensus Rating: Reduce (1 Buy Ratings, 4 Hold Ratings, 4 Sell Ratings)Consensus Price Target: $2.76 (2,972.0% Upside)Fisker Inc. develops, manufactures, markets, leases, or sells electric vehicles. It operates through three segments: The White Space, The Value Segment, and The Conservative Premium segments. The company is also involved in asset-light automotive business. In addition, it offers fisker flexible platform agnostic design, a process that develops and designs electric vehicles in specific segment size. The company was incorporated in 2016 and is headquartered in Manhattan Beach, California. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Sintx TechnologiesNASDAQ:SINTStock Price: $0.05P/E Ratio: -0.01Market Cap: $1.06 millionAverage Trading Volume: 23.81 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ASintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.#3 - Pineapple EnergyNASDAQ:PEGYStock Price: $0.05P/E Ratio: -0.03Market Cap: $3.36 millionAverage Trading Volume: 14.49 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.50 (4,671.0% Upside)Pineapple Energy Inc. engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. The company develops and manufactures energy management software and hardware, such as energy management control devices on solar systems that are paired with batteries. It primarily serves residential homeowners, as well as commercial owners, other municipal customers, energy services companies, and other utilities. Pineapple Energy Inc. was founded in 1969 and is based in Minnetonka, Minnesota.#4 - AtrecaNASDAQ:BCELStock Price: $0.09 (-$0.01)P/E Ratio: -0.04Market Cap: $3.57 millionAverage Trading Volume: 6.13 million sharesConsensus Rating: Hold (0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (4,334.6% Upside)Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.#5 - Gamida CellNASDAQ:GMDAStock Price: $0.01P/E Ratio: -0.02Market Cap: $2.23 millionAverage Trading Volume: 9.20 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.75 (32,658.6% Upside)Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.#6 - InvitaeNYSE:NVTAStock Price: $0.00P/E Ratio: 0.00Market Cap: $801,000.00Average Trading Volume: 23.72 million sharesConsensus Rating: Strong Sell (0 Buy Ratings, 0 Hold Ratings, 3 Sell Ratings)Consensus Price Target: $1.00 (33,233.3% Upside)Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details#7 - CURO GroupNYSE:CUROStock Price: $0.07P/E Ratio: -0.01Market Cap: $2.93 millionAverage Trading Volume: 984,281 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.00 (4,130.1% Upside)CURO Group Holdings Corp., together with its subsidiaries, provides consumer finance products in the United States and Canada. The company offers secured and unsecured installment loans, revolving line of credit, and single-pay loans; and credit protection insurance, check cashing, money transfer, foreign currency exchange, and other ancillary financial products and services, as well as reloadable prepaid debit cards and demand deposit accounts. The company also provides loans through online. It operates under the Covington Credit, Heights Finance, Quick Credit, Southern Finance, First Heritage Credit, Cash Money, LendDirect, and Flexiti brands. The company was formerly known as Speedy Group Holdings Corp. and changed its name to CURO Group Holdings Corp. in May 2016. CURO Group Holdings Corp. was founded in 1997 and is headquartered in Chicago, Illinois.#8 - Nevada CopperOTCMKTS:NEVDFStock Price: $0.08 (+$0.01)Average Trading Volume: 311,547 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ANevada Copper Corp. engages in the exploration, development, and operation of mineral properties in Nevada. The company explores for copper, gold, silver and iron magnetite ores. It holds 100% interests in the Pumpkin Hollow Copper property that consist of approximately 28.8 square-mile land patented claims located in Yerington, Nevada. Nevada Copper Corp. was incorporated in 1999 and is based in Vancouver, Canada.#9 - Motus GINASDAQ:MOTSStock Price: $0.07P/E Ratio: 0.00Market Cap: $380,000.00Average Trading Volume: 297,802 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $28.88 (40,004.2% Upside)Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.#10 - Evofem BiosciencesNASDAQ:EVFMStock Price: $0.01P/E Ratio: 0.00Market Cap: $790,000.00Average Trading Volume: 684,874 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.#11 - Aridis PharmaceuticalsNASDAQ:ARDSStock Price: $0.06P/E Ratio: -0.37Market Cap: $2.83 millionAverage Trading Volume: 96,778 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.00 (3,289.8% Upside)Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details#12 - Better TherapeuticsNASDAQ:BTTXStock Price: $0.01P/E Ratio: -0.01Market Cap: $560,000.00Average Trading Volume: 461,144 sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.00 (59,900.0% Upside)Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.#13 - MovellaNASDAQ:MVLAStock Price: $0.02Market Cap: $1.01 millionAverage Trading Volume: 144,639 sharesConsensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.45 (12,150.0% Upside)Movella Holdings Inc. operates as a full-stack provider of sensors, software, and analytics that enable the digitization of movement in the United States. Its real-time character movement in digital environments transforms movement into digital data that provides actionable insights. The company offers Xsens 3D Body Motion Systems comprises wearable sensor systems and motion capture solutions, including MVN Animate or MVN Analyze software, a full-body wearable sensor system, which captures the motion of the human body. It also provides Xsens sensor modules that enables customers to accelerate the development of motion-based applications; and DOT wearables for analysis and reporting of human kinematics. In addition, the company offers Kinduct human performance platform that provides biomechanical, biometric, and objective data for athletic performance, wellness, and injury risk. It serves the entertainment, health and sports, and automation and mobility markets. Movella Holdings Inc. is based in Henderson, Nevada.#14 - Evelo BiosciencesNASDAQ:EVLOStock Price: $0.04 (-$0.01)P/E Ratio: 0.00Market Cap: $826,000.00Average Trading Volume: 40,147 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.#15 - Nemaura MedicalNASDAQ:NMRDStock Price: $0.04P/E Ratio: -0.11Market Cap: $1.55 millionAverage Trading Volume: 36,516 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.50 (5,713.3% Upside)Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.#16 - Bellerophon TherapeuticsNASDAQ:BLPHStock Price: $0.06P/E Ratio: -0.07Market Cap: $765,000.00Average Trading Volume: 24,143 sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.00 (3,100.0% Upside)Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details#17 - MetaWorks PlatformsOTCMKTS:MWRKStock Price: $0.02Market Cap: $1.74 millionAverage Trading Volume: 82,061 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AMetaWorks Platforms, Inc. provides blockchain and Web3 development platform. It offers turnkey set of services for companies to develop and integrate blockchain and cryptocurrency technologies into their business operations. The company provides business development and technical services; blockchain and technology program management services; customer development services; business launch services; and post-business launch support services. The company was formerly known as CurrencyWorks Inc. and changed its name to MetaWorks Platforms, Inc. in August 2022. MetaWorks Platforms, Inc. was incorporated in 2010 and is based in Fairfield, California.#18 - Labrador Iron MinesOTCMKTS:LBRMFStock Price: $0.05Average Trading Volume: 20,857 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ALabrador Iron Mines Holdings Limited, a mineral resource company, engages in the exploration, development, and mining of iron ore projects in Canada. Its flagship project is the Houston project, which is an open pit direct shipping iron ore project located near the town of Schefferville. The company was incorporated in 2007 and is headquartered in Toronto, Canada.#19 - SQZ BiotechnologiesOTCMKTS:SQZBStock Price: $0.05P/E Ratio: -0.02Market Cap: $1.47 millionAverage Trading Volume: 19,270 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ASQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.#20 - Eguana TechnologiesOTCMKTS:EGTYFStock Price: $0.01Average Trading Volume: 91,097 sharesConsensus Rating: Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $0.90 (11,150.0% Upside)Eguana Technologies Inc. designs and manufactures residential and commercial energy storage systems for fuel cell, photovoltaic, and battery applications in Canada, Asia, Australia, Europe, and the United States. The company provides its products under the Enduro, Evolve, and Elevate brand names. The company was formerly known as Sustainable Energy Technologies Ltd. and changed its name to Eguana Technologies Inc. in September 2013. Eguana Technologies Inc. is headquartered in Calgary, Canada.#21 - KWG GroupOTCMKTS:KWGPFStock Price: $0.06Average Trading Volume: 10,000 sharesConsensus Rating: Sell (0 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)Consensus Price Target: N/AKWG Group Holdings Limited, together with its subsidiaries, engages in the property development and investment, and hotel operation businesses. Its property portfolio includes mid- to high-end residential properties, serviced apartments, villas, offices, hotels, and shopping malls. The company was formerly known as KWG Property Holding Limited and changed its name to KWG Group Holdings Limited in August 2018. KWG Group Holdings Limited was founded in 1995 and is headquartered in Guangzhou, the People's Republic of China.#22 - Horizonte MineralsOTCMKTS:HZMMFStock Price: $0.01Average Trading Volume: 60,667 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AHorizonte Minerals Plc, together with its subsidiaries, engages in the exploration and development of mineral projects in Brazil. The company primarily explores for nickel deposits, as well as cobalt deposits. It holds 100% interest in the Araguaia ferronickel; and the Vermelho Nickel-Cobalt project in the eastern part of the Carajás mining district. The company is headquartered in London, the United Kingdom.#23 - PT Sarana Menara Nusantara Tbk.OTCMKTS:SMNUFStock Price: $0.03P/E Ratio: 0.00Average Trading Volume: 6,367 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/APT Sarana Menara Nusantara Tbk. owns and operates telecommunication towers for wireless operators in Indonesia. It operates through two segments, Tower Rental, and Other Services. The company offers wireline telecommunication services to provide internet broadband and virtual private network; fiber to the home (FTTH) telecommunication services to build and manage fiber optic infrastructure; and very small aperture terminal (VSAT) solution to facilitate telecommunication services using satellite technology to remote locations. It also offers telecommunication equipment trading, construction, and installation services; system communication data, internet interconnection, satellite telecommunication, payment, hosting and related services. In addition, the company owns and rents real estate properties; trades in various goods; and wholesales and retails computer and computer equipment. Further, it engages in the management consulting; electrical power support; and electric power generation activities. The company was founded in 2008 and is headquartered in Kudus, Indonesia. PT Sarana Menara Nusantara Tbk. is a subsidiary of PT Sapta Adhikari Investama.#24 - KaspienNASDAQ:KSPNStock Price: $0.01P/E Ratio: 0.00Market Cap: $50,000.00Average Trading Volume: 8,648 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AKaspien Holdings Inc. operates an e-commerce services provider. Its platform of software and services enable brand's online distribution channel on digital marketplaces, such as Amazon, Walmart, Target, and others. The company's technology-enabled retailer that delivers brand partners across Amazon.com US, Amazon.com Canada, Target.com, and Walmart.com online marketplaces. The company was formerly known as Trans World Entertainment Corporation and changed its name to Kaspien Holdings Inc. in September 2020. Kaspien Holdings Inc. was incorporated in 1972 and is headquartered in Spokane, Washington.#25 - SIGNA Sports UnitedNYSE:SSUStock Price: $0.00Market Cap: $78,000.00Average Trading Volume: 214,531 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.90 (949,900.0% Upside)SIGNA Sports United N.V. operates online sports web shops in the European Union, Switzerland, Norway, the United Kingdom, and the United States. Its product categories include bike, tennis/racket sports, outdoor, and team sports and athleisure. The company is headquartered in Berlin, Germany. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Apple’s Earnings Show Investors Its Strength and Its Weakness DraftKings Q1: Strong Customer Acquisition and Product Innovation For Cardinal Health, the Proof Will be in Its Performance Carvana’s Q1 Earnings: A Profitability U-Turn Wall Street Believes in First Solar Stock’s Bull Cycle Starbucks: Indicators Turns Bearish, New Lows in Sight Yum! Brands: Can Digital Strength Offset Same-Store Declines? AMD is Down 35%. Now is the Time to Buy the Dip Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.